Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €26.26 EUR
Change Today -0.095 / -0.36%
Volume 0.0
GOV On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 1:51 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

insulet corp (GOV) Snapshot

Open
€26.64
Previous Close
€26.36
Day High
€27.40
Day Low
€26.26
52 Week High
12/8/14 - €38.80
52 Week Low
05/6/15 - €22.25
Market Cap
1.5B
Average Volume 10 Days
10.0
EPS TTM
--
Shares Outstanding
56.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSULET CORP (GOV)

insulet corp (GOV) Related Bloomberg News

View More Bloomberg News

insulet corp (GOV) Related Businessweek News

No Related Businessweek News Found

insulet corp (GOV) Details

Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Management System (OmniPod System), which consists of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and personal diabetes manager, a handheld wireless device. It also sells blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The company sells and markets its OmniPod System to diabetes practitioners, academic medical centers, clinics, people with insulin-dependent diabetes, third-party payors, and government agencies, as well as third-party distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

519 Employees
Last Reported Date: 02/26/15
Founded in 2000

insulet corp (GOV) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $182.5K
Executive Vice President of Human Resources a...
Total Annual Compensation: $49.7K
Compensation as of Fiscal Year 2014.

insulet corp (GOV) Key Developments

Insulet Corporation Announces Changes

Insulet Corporation announced that Mark Licari has been promoted to Vice President of Global Manufacturing and Operations, effective immediately. Mr. Licari, who recently joined Insulet as Vice President of Manufacturing Operations and R&D for Insulet's Drug Delivery business. David Colleran, J.D. joined Insulet on June 29, 2015 and after a short transition, will assume the role of Vice President and General Counsel, succeeding R. Anthony Diehl, who has resigned. Mr. Colleran most recently served as Vice President and General Counsel for the Medical Supplies Sector of Covidien. Mr. Licari and Mr. Colleran will report directly to Patrick Sullivan, President and Chief Executive Officer.

Insulet Corporation Announces Resignation of Patrick Ryan as Chief Operating Officer

Insulet Corporation announced that Patrick Ryan notified the company that he will resign as the chief operating officer of the company as of June 29, 2015. Mr. Ryan has agreed to continue his employment with the company in a non-executive capacity through July 10, 2015 to assist in the transition of his responsibilities.

Brower Piven Announces Class Action Lawsuit Against Insulet Corp

Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Insulet Corp. securities during the period between February 27, 2013 and April 30, 2015, inclusive. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the company was experiencing slower demand for its products and experiencing problems with its sales and marketing efforts. According to the complaint, following the company’s April 30, 2015 disclosure of its first quarter 2015 financial results, including a statement that deliveries and shipments planned for the first quarter were now expected to be realized during the remainder of 2015, the value of Insulet shares declined significantly.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GOV:GR €26.26 EUR -0.095

GOV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.41 USD -0.11
DexCom Inc $79.36 USD -0.41
Smiths Group PLC 1,162 GBp +12.00
Takeda Pharmaceutical Co Ltd ¥5,997 JPY 0.00
Tandem Diabetes Care Inc $10.50 USD -0.12
View Industry Companies
 

Industry Analysis

GOV

Industry Average

Valuation GOV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 21.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.